Pfizer Celecoxib has met its primary endpoint in a Phase IV trial evaluating its effects on blood pressure in paediatric patients with juvenile idiopathic arthritis (JIA).

No virtual difference in the primary and secondary endpoints, systolic blood pressure and diastolic blood pressure, between the celecoxib and naproxen treatment groups were noted.

A similar safety profile was observed in both the groups. Headache, nausea and joint aches were the most common adverse events reported in both treatment groups.

The double-blind, multicentre study was conducted for six weeks to evaluate 50mg or 100mg Celecoxib twice a day or 7.5mg/kg naproxen twice a day.

A total of 201 patients from 10 different countries diagnosed with JIA, including patients with oligoarticular JIA (where few joints are affected) and polyarticular JIA (where many joints are affected), participated in the study.

The company carried out the study as part of a post-marketing commitment to the US Food and Drug Administration for Celebrex.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Image: Pfizer celebrex has been approved by the FDA for the relief of the signs and symptoms of JRA in pediatric patients two years of age and older. Photo: Courtesy of Jim Henderson.